US 12,410,253 B2
Compositions comprising anti-NRP2 antibodies
Luke Burman, San Diego, CA (US); Yeeting Chong, San Diego, CA (US); Leslie Ann Greene, San Diego, CA (US); David King, Encinitas, CA (US); Zhiwen Xu, La Jolla, CA (US); and Ryan Andrew Adams, San Diego, CA (US)
Assigned to aTyr Pharma, Inc., San Diego, CA (US)
Filed by aTyr Pharma, Inc., San Diego, CA (US)
Filed on Sep. 28, 2023, as Appl. No. 18/477,113.
Application 18/477,113 is a division of application No. 17/062,100, filed on Oct. 2, 2020, granted, now 11,807,687.
Claims priority of provisional application 63/024,960, filed on May 14, 2020.
Claims priority of provisional application 62/910,042, filed on Oct. 3, 2019.
Prior Publication US 2024/0092917 A1, Mar. 21, 2024
Int. Cl. A61K 39/395 (2006.01); A61P 35/04 (2006.01); C07K 16/28 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/2863 (2013.01) [A61K 39/3955 (2013.01); A61P 35/04 (2018.01); A61K 39/001103 (2018.08); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/33 (2013.01); C07K 2317/52 (2013.01)] 15 Claims
OG exemplary drawing
 
1. A therapeutic composition, comprising a pharmaceutically-acceptable carrier and at least one antibody or antigen-binding fragment thereof that specifically binds to a human neuropilin-2 (NRP2) polypeptide at an epitope in the neuropilin a2 domain of human NRP2, wherein the at least one antibody or antigen-binding fragment thereof comprises:
a heavy chain variable region (VH) sequence that comprises complementary determining region VHCDR1, VHCDR2, and VHCDR3 sequences; and a light chain variable region (VL) sequence that comprises complementary determining region VLCDR1, VLCDR2, and VLCDR3 sequences, wherein:
the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 31-33, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs: 34-36, respectively; or
the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 37-39, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs: 40-42, respectively,
including variants thereof that differ by substitution of one amino acid in VHCDR3, VLCDR1 and/or VLCDR3, wherein the VHCDR3 sequence comprises SEQ ID NO: 81, the VLCDR1 sequence comprises SEQ ID NO: 82, and the VLCDR3 sequence comprises SEQ ID NO: 83, wherein X5 of SEQ ID NO: 83 is F, G, I, K, L, N, R, T, V, or Y.